Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

sontuzumab

A humanized monoclonal antibody directed against the tumor associated antigen (TAA) mucin-1 (MUC1), with potential antineoplastic activity. Upon administration, sontuzumab targets and binds to MUC1 expressed on the surface of tumor cells, which may activate the immune system to induce an antibody-dependent cellular cytotoxicity (ADCC) against MUC1-expressing tumor cells. MUC1, a glycoprotein overexpressed on the surface of a variety of cancer cells, plays a key role in tumor cell survival and proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	epitumomab
Foreign brand name:	Therex
Abbreviation:	HuHMFG1
Code name:	AS1402 R1550

sontuzumab

Search NCI's Drug Dictionary